Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Spherix Global Insights

< Previous 1 2 3 4 5 6 Next >
News headline image
Fibrosis Emerges as Key Opportunity for TL1A Therapies in Crohn’s Disease, Spherix Global Insights Finds
From Spherix Global Insights
Via GlobeNewswire
News headline image
83% of Dermatologists See Extreme Unmet Need in Severe Hidradenitis Suppurativa as Bimzelx Overtakes Humira, Nears Cosentyx, and Pipeline Interest Surges
From Spherix Global Insights
Via GlobeNewswire
News headline image
One in Three Treated Patients with Cutaneous Lupus Without Systemic Involvement Have Moderate-to-High Disease Activity, Spherix Global Insights Finds
From Spherix Global Insights
Via GlobeNewswire
News headline image
Spherix Global Insights Finds Icotyde Poised to More Than Double Share as New Oral Therapy May Delay Biologic Use
From Spherix Global Insights
Via GlobeNewswire
News headline image
Retatrutide Leads Obesity Pipeline Recall Amid Limited Physician Awareness of Other Treatment News, Spherix Global Insights Finds
From Spherix Global Insights
Via GlobeNewswire
News headline image
Just One in Ten Rheumatologists Satisfied with Current Systemic Sclerosis Treatments as Emerging Therapies Raise Expectations, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Sotyktu Gains Ground in Psoriatic Arthritis, but Rheumatologists Remain Selective as Its Role in the Treatment Algorithm Takes Shape, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Spherix Global Insights Launches Obesity Franchise as Weight Management Impacts Commercial Strategy Across Related Markets
From Spherix Global Insights
Via GlobeNewswire
News headline image
Autoimmune CAR T Safety Events Reshape Rheumatologist Sentiment, but Autologous CAR T Retains Lead, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Spherix Global Insights Builds on Respiratory Research Portfolio to Support Continued Growth and Broader Indication Coverage
From Spherix Global Insights
Via GlobeNewswire
News headline image
Dupixent, Skyrizi, Tremfya, Keytruda, Darzalex, and Hemlibra Among Patient Support Leaders as New Spherix Global Insights Research Reveals What Sets Top Programs Apart
From Spherix Global Insights
Via GlobeNewswire
News headline image
Spherix Global Insights Research Reveals a CKD Symptom Disconnect: 86% of Patients Report Symptoms While Nephrologists Classify Nearly Half as Asymptomatic
From Spherix Global Insights
Via GlobeNewswire
News headline image
Japanese Gastroenterologists Support Earlier Advanced Therapy in Ulcerative Colitis, but Practice Lags Behind Belief, Spherix Global Insights Finds
From Spherix Global Insights
Via GlobeNewswire
News headline image
Rosnilimab Emerges as a Potential Advance in Rheumatoid Arthritis as Physicians Look to the Next Wave of Pipeline Innovation
From Spherix Global Insights
Via GlobeNewswire
News headline image
Earlier Intervention Reshapes the Multiple Myeloma Treatment Continuum as Advanced Therapy Options Expand, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
COPD Treatment Landscape Expands, Yet Significant Gaps in Disease Control and Access Persist, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Nearly two-thirds of Nephrologists Cite Limited Treatment Options as Alport Syndrome’s Greatest Challenge Amid Growing Pipeline Interest, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Neurologists Interested in Cell Therapy in Neuro-Immune Diseases, but Safety and Logistics Will Shape Adoption, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
As Sickle Cell Innovation Accelerates, Hematologists Signal Demand for a Broader Treatment Arsenal Beyond Gene Therapy
From Spherix Global Insights
Via GlobeNewswire
News headline image
Spherix Global Insights Finds One-Third of Treated MASH Patients Remain Inadequately Controlled Even as Prescription Use Expands
From Spherix Global Insights
Via GlobeNewswire
News headline image
Bimzelx Momentum Builds as Rheumatologists Look Beyond TNFs to the Next Wave of axSpA Therapies, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Gene Therapy Remains Top-of-Mind in Hemophilia Despite Recent Market Contraction, as Physicians and Patients Raise the Bar for Success
From Spherix Global Insights
Via GlobeNewswire
News headline image
IL-23 Inhibitors Gain Physician Preference for IBD Across Europe, Yet Actual Use Continues to Lag, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Spherix Global Insights Launches RapidPulse Dynamix™ to Support Time-Sensitive Market Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
New Cross-Study Analysis from Spherix Global Insights Combines Physician, Dietitian and Patient Chart Data to Show Access Barriers Still Curbing Xphozah Uptake Ahead of the TDAPA Cliff
From Spherix Global Insights
Via GlobeNewswire
News headline image
Subcutaneous PD-1 Inhibitors Transition from Novelty to Routine Care as Oncologists Tailor Use by Tumor Type, According to Spherix Global Insights
From Spherix Global Insights
Via GlobeNewswire
News headline image
Sotyktu Begins Defining a New Oral Treatment Segment in Psoriatic Arthritis, According to Spherix Global Insights Launch Research
From Spherix Global Insights
Via GlobeNewswire
News headline image
Spherix Global Insights Reports Persistent High Unmet Need in Europe's Evolving MASH Market
From Spherix Global Insights
Via GlobeNewswire
News headline image
Physicians and Patients Agree Lupus Care Is Improving, But Both Say Meaningful Gaps Remain
From Spherix Global Insights
Via GlobeNewswire
News headline image
CTD-ILD Enters New Treatment Era, but Physicians Still See Significant Unmet Need
From Spherix Global Insights
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.